CIA
VIR icon

Capital Impact Advisors’s Vir Biotechnology VIR Stock Holding History

Capital Impact Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,233
Closed -$177K – 167
2023
Q2 		$177K Hold
7,233
– – 0.2% 159
2023
Q1 		$168K Sell
7,233
-5,963
-45% -$153K 0.21% 155
2022
Q4 		$334K Hold
13,196
– – 0.33% 132
2022
Q3 		$360K Buy
13,196
+1,130
+9% +$28.7K 0.36% 119
2022
Q2 		$307K Sell
12,066
-3,332
-22% -$77.8K 0.28% 154
2022
Q1 		$396K Buy
+15,398
New +$457K 0.29% 153

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Impact Advisors's VIR Position: Q3 2023 in Review

Capital Impact Advisors sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 7,233 shares — an estimated $177K sold.

Capital Impact Advisors first reported a position in VIR in Q1 2022 and held it in 6 quarters. The position peaked at $396K in Q1 2022. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Capital Impact Advisors reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Capital Impact Advisors sold 7,233 Vir Biotechnology shares in Q3 2023, an estimated $177K.
  • Capital Impact Advisors first reported a position in Vir Biotechnology in Q1 2022 and held it in 6 quarters.
  • Capital Impact Advisors's Vir Biotechnology position peaked at $396K in Q1 2022.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Capital Impact Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.